The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Landesforschungspreis Baden-Württemberg für Angewandte Forschung for Scientist of CRC 1160
Feb 27, 2026 –
Prof. Dr. Robert Zeiser, principal investigator of CRC 1160 (B09, B10), has been awarded the Landesforschungspreis Baden-Württemberg für Angewandte Forschung for his pioneering work in cancer medicine.
Publications
Polcik L, Pethe A, Ashok D, Tissino E, Fernández-Rego A, Pozzo F, Danner DJ, Holst M, Martines C, Hofmann K, Dimovski AJ, Kissel S, Härzschel A, Li L, Bittolo T, Andrieux G, Haslauer T, Höpner JP, Zaborsky N, Greil R, Miething C, Duque-Afonso J, Köhler N, Boerries M, Bomben R, Duyster J, Grosse R, Gaidano G, Zamò A, Zucchetto A, Carrasco YR, Efremov DG, Gattei V, Hartmann TN. 2026. CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL. Blood. 2026 Jun 25;147(26):3179-3194. doi: 10.1182/blood.2024027753.
Wächtershäuser KN, Schneider JV, Gessner A, Andrieux G, Kur IM, Duschek N, Weigert A, Boerries M, Rieger MA, Stelzer EHK, Pampaloni F, van Wijk SJL. 2026. Necroptosis triggers inflammatory interferon signatures in patient-derived metastatic breast cancer organoids. Signal Transduct Target Ther. 2026 Jun 1;11(1):204. doi: 10.1038/s41392-026-02755-9.
Woessner NM, Keller B, Minguet S. 2026. LCK at the crossroad of immunodeficiency and autoimmunity: Mechanisms and therapeutic opportunities. Immunol Lett. 2026 Jun;279:107126. doi: 10.1016/j.imlet.2025.107126.
Luxenburger H, Thimme R, Hofmann M. 2026. T cell adaptation in chronic infections and tumors. Cell Mol Immunol. 2026 May;23(5):440-456. doi: 10.1038/s41423-026-01405-y.
Maccari ME, König C, Andrieux G, Kury P, Berger SA, Mann J, Kelly B, Völkl S, Huang C, Helmstädter M, Lagies S, Fischer M, Baixauli F, Gorka O, Groß O, Hufnagel M, Salou S, Farmand S, Heine S, Schuster V, Willenbacher W, Dückers G, Grimbacher B, Warnatz K, Kapp FG, Lorenz M, Groß M, Wittner J, Elling R, Scorrano L, Koenig IA, Bengsch B, Speckmann C, Kammerer B, Börries M, Schwarz K, Hertel J, Pearce EL, Ehl S, Klein Geltink RI, Rensing-Ehl A. 2026. FAS-controlled T cells drive lymphoproliferation through glycolysis without effector differentiation. J Hum Immun. 2026 May 13;2(4):e20250233. doi: 10.70962/jhi.20250233.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency (IFI),
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
